

1 **Systemic and Genetic Risk Factors for Reticular Macular Disease and Soft Drusen in Age-**
2 **Related Macular Degeneration**

3
4 **Short title: Risk Factors for SDDs and Soft Drusen in AMD**

5
6 Robert J. Thomson, BS¹
7 Joshua Chazaro, BS²
8 Oscar Otero-Marquez, MD³
9 Gerardo Ledesma-Gil, MD^{3,4,5}
10 Yuehong Tong, PhD^{3,6}
11 Arielle C. Coughlin, BA⁷
12 Zachary R. Teibel, MD⁸
13 Sharmina Alauddin, MD³
14 Katy Tai, BA³
15 Harriet Lloyd, BA³
16 Maria Scolaro, MA⁴
17 Arun Govindaiah, MS⁷
18 Alauddin Bhuiyan, PhD⁶
19 Mandip S. Dhamoon, MD⁸
20 Avnish Deobhakta, MD³
21 Jagat Narula, MD⁹
22 Richard B. Rosen, MD³
23 Lawrence A. Yannuzzi, MD⁴
24 K. Bailey Freund, MD^{4,10}
25 R. Theodore Smith, MD PhD^{3,6}

26
27
28 ¹McGovern Medical School at The University of Texas Health Science Center, Houston, Texas.

29 ²Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.

30 ³Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York,
31 New York, USA

32 ⁴Vitreous Retina Macula Consultants of New York, New York, USA

33 ⁵Retina Department, Institute of Ophthalmology Fundación Conde de Valenciana, Mexico City,
34 Mexico

35 ⁶Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New
36 York, USA

37 ⁷Icahn School of Medicine at Mount Sinai, New York, New York, USA

38 ⁸Hackensack University Medical Center, Hackensack, New Jersey, USA

39 ⁷iHealthscreen Inc., New York, USA

40 ⁸Department of Neurology, Icahn School of Medicine at Mount Sinai

41 ⁹Department of Cardiology, Icahn School of Medicine at Mount Sinai

42 ¹⁰Department of Ophthalmology, NYU Grossman School of Medicine. New York, New York,
43 USA

44

45 Corresponding Author:

46 R. Theodore Smith, MD, PhD

47 New York Eye and Ear Infirmary of Mount Sinai, 310 E 14th St, New York, NY, 10003, USA.

48 E-mail address: rts1md@gmail.com
49

50 **Competing interests:** Richard B. Rosen is a consultant to OptoVue, Boehringer-Ingelheim,
51 Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys and Teva. He has
52 personal financial interests in Opticology, Guardion and CellView. K. Bailey Freund is a
53 consultant to Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering and Novartis. He
54 receives research funding from Genentech/Roche. R Theodore Smith is a consultant to Ora
55 Technologies. The remaining authors have no relevant disclosures.

56

57 **Funding:** Regeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent
58 Blindness Challenge Grant, Macula Foundation (KBF), Bayer-Global Ophthalmology Awards
59 (GLG), International Council of Ophthalmology-Alcon Fellowship (OOM), New York Eye and
60 Ear Infirmary Foundation (SA).

61

62 **Keywords:** age related macular degeneration; choroid; cardiovascular disease; drusen; genetics;
63 reticular macular disease; risk factors; stroke; subretinal drusenoid deposits.

64

65 **Summary Statement:** Two phenotypes of age-related macular degeneration, soft drusen and
66 reticular macular disease (the combination of subretinal drusenoid deposits and choriocapillaris
67 insufficiency), are shown here to have distinct systemic vascular, serum, and genetic risks. These
68 findings support the concept that these phenotypes actually represent distinct disease processes.

69

70

71

72

73 **ABSTRACT**

74

75 Purpose: Soft drusen and subretinal drusenoid deposits (SDD) aka reticular macular disease
76 (RMD) characterize two pathways to advanced age-related macular degeneration (AMD). We
77 propose these pathways are distinct diseases, with distinct genetic risks, serum risks and
78 associated systemic diseases.

79

80 Methods: 126 Subjects with AMD had: retinal imaging for RMD status, serum risks, genetic
81 testing, and histories of cardiovascular disease (CVD) and stroke.

82

83 Results: 62 subjects had RMD, 64 were nonRMD (drusen only), 51 had CVD or Stroke.

84 RMD correlated significantly with: *ARMS2* risk allele ($p=0.019$); lower mean serum HDL

85 (61 ± 18 vs. 69 ± 22 mg/dl, $p=0.038$, t test); CVD and stroke ($34/51$ RMD, $p=0.001$).

86 NonRMD correlated/trended with: *APOE2* ($p=0.032$) and *CETP* ($p=0.072$) risk alleles. 97

87 subjects total had some drusen, which correlated with *CFH* risk ($p=0.016$). Multivariate

88 independent risks for RMD were: CVD and Stroke ($p=0.008$), and *ARMS2* homozygous risk ($p=$

89 0.038).

90

91 Conclusion: The RMD and soft drusen AMD pathways have distinct systemic associations,

92 serum and genetic risks. RMD is associated with CVD and stroke, *ARMS2* risk, and lower HDL;

93 drusen with *CFH* risk and two lipid risk genes. These pathways appear to be distinct diseases

94 leading to advanced AMD.

95

96 Multiple systemic, environmental and genetic risk factors have been identified for the
97 complex disease of Age-related macular degeneration (AMD). However, assessment of the
98 disease impact of variables from so many sectors is difficult, and the pathogenic mechanisms
99 driving the disease itself are largely uncertain. We herein suggest that this problem be broken
100 into two largely independent disease pathways, which could be more easily analyzed separately.
101 These two pathways involve distinct lipid-laden deposits; one with lesions of soft drusen beneath
102 the retinal pigmented epithelium (RPE), and one with subretinal drusenoid deposits (SDD) above
103 the RPE¹ (**Figure 1**). Both deposits can occur in the same eye (**Figure 1B**), and both can
104 progress to advanced AMD,²⁻⁴ of which SDD, aka reticular pseudodrusen (RPD), confers twice
105 the risk.^{5,6,7}

106 An important further consideration is functional: the RPE is supplied by the choroidal
107 vasculature/choriocapillaris (CC).⁸ CC insufficiency uniformly accompanies SDD on
108 indocyanine green angiography⁹ and non-invasive optical coherence tomography angiography
109 (OCTA) ¹⁰ often accompanied by choroidal thinning and loss of choroidal volume.¹¹ SDD are
110 topographically related to choroidal watershed zones, suggesting hypoxia in their pathogenesis.¹²
111 Hence CC insufficiency and SDDs have logically been combined together as the reticular
112 macular disease (RMD) phenotype of AMD⁹, and we will refer to this phenotype unambiguously
113 as SDD or RMD.

114 We propose these hypotheses to be explored initially herein and as a working basis for
115 productive future research in AMD.

116 **Hypotheses: 1.** The SDD and soft drusen pathways do not have the same systemic
117 associations, serum risks or genetic risks. **2.** These pathways are in fact distinct diseases that only
118 merge in their common outcome in what is truly a single disease, advanced AMD (atrophic

119 and/or exudative). **3.** Patient care could be personalized by consideration of the risk factors
120 pertinent to the disease pathway operative in a given individual. Research on the pathogenesis of
121 AMD could be well-served by identifying and differentiating those risk factors that apply
122 specifically to only one or the other pathway, enabling focused attention to specific risks and
123 single pathways, with corresponding simplification and higher chance of success.

124 **Hypothesis 1** will be explored, amplified and supported in this paper.

125 **Hypothesis 2.** Evidence is presented here in the categories mentioned that SDD/RMD
126 and soft drusen are hallmarks of distinct diseases. Broad and persuasive support, to be
127 summarized, is already established.

128 **Hypothesis 3** is theoretically self-evident, given **Hypotheses 1 and 2,**

129 Regarding **Hypothesis 2:** established multimodal imaging and anatomic distinctions
130 between the phenotypes include: scanning laser ophthalmoscopy (SLO), with autofluorescence
131 (AF) and near-infrared reflectance (NIR) imaging, which clearly identifies SDD as
132 hypoautofluorescent on AF and hyporeflectant on NIR,⁹ properties not shared by drusen;
133 histopathological identification of SDD¹³ in the subretinal space, with drusen in the sub-RPE
134 space, confirmed *in vivo* by spectral domain OCT (SD-OCT),¹⁴ with choroidal thinning
135 commonly found with SDD; and topographic localization of SDD with rod photoreceptors.¹⁵
136 SDD are associated epidemiologically with female gender and decreased longevity,⁵
137 systemically with coronary artery disease (CAD) in small case-control studies,^{2 3} since
138 confirmed with OCTA documentation of CC insufficiency,¹⁶ and with cardiovascular cause of
139 death in donors.¹⁷ SDD carry a worse prognosis for progression to advanced AMD⁶ and differing
140 associated subtypes of advanced AMD (both exudative, type 3 choroidal neovascularization¹⁸ and

141 non-exudative, multilobular geographic atrophy⁷), biochemical composition,¹ and functional
142 impact on rod-mediated dark adaption.¹⁹
143 Herein, we extended these disease distinctions with data on AMD risk alleles, serum risk
144 markers, and associations with vascular disease, as well as other demographic, ocular and
145 systemic features. We classified AMD patients into RMD (RMD present, either eye, +/- drusen)
146 with obligate underlying CC deficiency or non-RMD (large soft drusen only) by retinal imaging
147 for comparison

148

149 **Methods**

150 This was a multicenter prospective study conducted at two tertiary vitreoretinal referral
151 centers in New York City, USA: Vitreous Retina Macula Consultants of New York (LY, KBF),
152 and Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai School of
153 Medicine (MSSM) (RBR, RTS), from January 2019 to January 2021. The institutional review
154 board of MSSM approved the study, which adhered to the tenets of the Declaration of Helsinki.
155 ClinicalTrials.gov Identifier: NCT04087356.

156

157 **Inclusion and Exclusion Criteria.**

158 All patients older than 50 years, diagnosed with RMD/SDD and/or large soft drusen
159 lesions of AMD in either eye, who signed informed consent, and completed a study-related
160 questionnaire were included. Exclusion criteria were patients with other retinal degeneration and
161 vascular diseases, prior retinal surgery (except intravitreal injections), poor-quality imaging
162 and/or inconclusive medical or macular diagnoses.

163

164 **Patient Evaluation.**

165 Work-up included best-corrected visual acuity, slit lamp biomicroscopy, intraocular
166 pressure (mmHg), blood samples for 9 AMD risk alleles and vascular disease risk factors, age,
167 gender, race/ethnicity, relevant family history, smoking, medication, and medical/ocular history
168 specifically covering stroke and these heart disease histories: myocardial infarction, coronary
169 artery bypass grafting (CABG), angina, arrhythmia, positive stress test, positive cardiac
170 catheterization, stent, valve disease and congestive heart failure (CHF) of any cause. Cases
171 confirmed against medical records were included in the cardiovascular (CVD) and stroke group.

172

173 **Imaging.**

174 Volume SD-OCT scans (27 lines, automated retinal tracking, 16 scans averaged per line),
175 and *en face* AF and NIR scans (both 30 degrees) centered on the fovea on the Heidelberg
176 Spectralis HRA + OCT (Heidelberg engineering, Heidelberg, DE).

177

178 **Image Analysis.**

179 SDD were identified on SD-OCT imaging as lesions of intermediate reflectivity above
180 the RPE followed a published protocol² for presence and most advanced stage independently and
181 then to consensus by two retina specialists (GLG, OOM). Any differences were resolved by a
182 senior grader (RTS). AF and NIR images were used to confirm the presence of SDD as fairly
183 uniform hypoautofluorescent or hyporeflective lesions in compact distributions with well-
184 defined borders.⁹ RMD status was determined by the presence of SDD alone, relying on
185 significant literature uniformly demonstrating CC insufficiency^{9,10 12,20} Soft drusen were
186 identified on SD-OCT imaging as lesions of intermediate reflectivity on Bruch's membrane

187 (BrM) elevating the RPE (**Figure 1**). Pigment epithelial detachments (PEDs) were included with
188 soft drusen. Other drusen phenotypes of lesser prevalence (calcified drusen, cuticular drusen)
189 were not included. A large soft drusen was required to be >125 microns in diameter. Choroidal
190 thickness (CTh) was measured on a central SD-OCT scan (**Figure 1**).

191

192 **Serum CVD Risk Markers Analysis.**

193 Blood samples for risk biomarkers of CVD²¹ (high-density lipoprotein cholesterol [HDL-
194 c], low-density lipoprotein cholesterol [LDL-c], triglycerides [TG], total cholesterol [TC] and
195 high sensitivity C-reactive protein [hsCRP]) were rapidly centrifuged at 1800 g for 10 minutes
196 and refrigerated. Lipid levels were measured (Quest Diagnostics, Teterboro, NJ) by
197 spectrophotometry, and plasma levels of hsCRP, by Immunoturbidimetric Assay (Orion
198 Diagnostica, Finland).

199

200 **Genetic Analysis.**

201 Blood samples for DNA were immediately stored at - 70°C until shipped on dry ice to
202 LGC Genomics (LGC, Biosearch Technologies, Hoddesdon, UK). Genomic DNA was extracted
203 from peripheral blood leukocytes according to established protocols. Genotyping was carried out
204 using KASP (Kompetitive Allele-Specific PCR, LGC Genomics) genotyping assays designed to
205 each target variant, within 1536 well PCR plates. Fluorescence was detected using the BMG
206 Pherastar (BMG LABTECH GmbH, Ortenberg, DE) and genotyping calls assigned based on
207 cluster plots within the LGC Genomics Kraken software.

208 The samples were assessed for single-nucleotide polymorphisms in 9 genes associated
209 with AMD: *CFH* (Y402H allele), *ARMS2-HTRA1* (69S allele), *C3*, *C2/BF* (*BF* rs4151667, which

210 identifies the H10 haplotype of *C2/BF*), cholesteryl ester transfer protein (*CETP*), hepatic lipase
211 (*LIPC*), tissue inhibitor of metalloproteinase 3 (*TIMP3*), apolipoprotein genes (*APOE2* and
212 *APOE4*). All are risk alleles except for the protective *C2/BF*, *LIPC* and *APOE4* alleles.²²

213

214 **Statistical Analysis.**

215 Experts (AB, AG) used ‘IBM SPSS Statistics version 27’, ‘Waikato Environment for
216 Knowledge Analysis (WEKA) Version 3.8.5’, a data modeling tool, and Microsoft Excel 365.
217 Univariate statistics were chi square for categorical variables, two-tailed t-test for continuous
218 variables, with medians, ranges and/or interquartile ranges (IQRs) for non-normally distributed
219 data. Multivariate regression determined each variable’s significance ($p < 0.05$) after controlling
220 for all other covariates.

221

222 **Results**

223

224 **Demographics and clinical characteristics.**

225 62 subjects had SDD/RMD present (29 pure, without large soft drusen, and 33 mixed
226 cases) and 64, SDD absent (large soft drusen only). Five disagreements were resolved by
227 consensus without arbitration. For the RMD group, 67.7% were females and 32.3% were males.
228 The associations of demographic, ocular and clinical characteristics of patients with or without
229 RMD were not significantly different, except that acetylsalicylic acid (ASA) use was
230 significantly associated with RMD (53/62 RMD vs 30/64 nonRMD, $p = 0.007$), and mean CTh
231 was less in left eyes with RMD than in nonRMD left eyes (Mean 146 ± 58 vs. 177 ± 59 microns,

232 p= 0.003; median 161.5, range 78-228 microns vs. median 177.5, range 90-286 microns) as
233 shown in **Table 1**.

234

235 **Serum Risk Markers, CVD and Stroke.**

236 Cholesterol panel and hsCRP mean values for RMD and non-RMD subjects were not
237 significantly different, except mean HDL was lower in RMD (mean 61±18; median 57, IQR 19)
238 than non-RMD subjects (mean 69±22, p= 0.038; median 69, IQR 29) as depicted in **Table 2**.

239 Of the 126 subjects, 51 had CVD or stroke, 34/51 RMD (p= 0.001, chi square).

240 **Genetics.**

241 The *ARMS2* risk allele frequency was significantly higher, 41.6%, in the RMD group
242 than in the nonRMD group (28.5%, OR 1.79, 95% CI 1.15 - 3.03, p= 0.03).

243 The *CFH* risk allele frequencies were similar in the two groups (56% and 53.2%; p= 0.66).

244 Dividing the subjects analogously into Drusen (Drusen present, +/- RMD) or nonDrusen
245 (RMD only, no large soft drusen), the *CFH* risk allele frequency was significantly higher, 61.4%,
246 in the Drusen group than in the nonDrusen group (36.8%, OR 2.37, 95% CI 1.16-4.76, p=
247 0.016). All other findings with this subdivision were NS.

248

249 *APOE2* and *CETP* risk allele frequencies were higher in the nonRMD group than in the
250 RMD group (14.3% vs 5.9%, and 43.6% vs 32.5%, p= 0.03 and 0.07, respectively). Allele
251 frequencies and significance of correlations with RMD or nonRMD of haplotype-tagging single-
252 nucleotide polymorphisms (SNPs) from the AMD-associated Loci are shown in **Table 3**.

253

254 **Multivariate regression.**

255 Multivariate regression found CVD or stroke and *ARMS2* homozygous risk significant
256 for RMD risk ($p= 0.008$ and $p= 0.038$, respectively), after controlling for all other parameters.
257 ASA use, a *treatment* for many vascular diseases, was not analyzed for multivariate RMD risk,
258 considering the evident strong association of vascular diseases with RMD/SDD.

259

260 **Discussion.**

261 The central hypothesis presented in this paper is that the SDD/RMD and soft drusen
262 pathways of AMD are actually two separate, but often co-existing, diseases that may result in a
263 single disease outcome, advanced AMD. The phenomenon of multiple, separate disease
264 pathways resulting in the same poor outcome and organ dysfunction is often the norm in
265 medicine rather than the exception, e.g., the many unique paths to heart failure. As mentioned
266 before, evidence for this pathophysiologic distinction has already accumulated from diverse
267 disciplines: anatomy, histology, imaging, retinal function, clinical outcomes, biochemistry, and
268 choroidal vascular physiology. Indeed, if all these facts had been known at the outset with the
269 discovery of the new lesion of SDD, the recognition of a completely distinct disease process
270 would have likely been clear and immediate.

271 We have shown herein that the SDD/RMD and soft drusen pathways also differ
272 significantly in their systemic associations, serum risks and genetic risks. In total, we suggest the
273 evidence is persuasive. As a corollary, this construct further supports revising the term AMD to
274 be reserved for the outcomes now known as advanced AMD, with age-related maculopathy
275 (ARMD) applied to any precursor state: RMD, drusen, other.

276 The *ARMS2* risk allele significantly correlated with reticular macular disease (RMD), the
277 combined phenotype of SDD and choriocapillaris insufficiency, compared to soft drusen; and the

278 *CFH* risk allele significantly correlated with soft drusen compared to RMD. These results
279 replicate our previous discovery that *ARMS2* risk is significantly more correlated with RMD than
280 nonRMD/pure drusen in AMD.²³ The finding that *CFH* risk is significantly higher in all subjects
281 with drusen than pure RMD, is new, but is consistent with our 2011 paper. This still leaves the
282 possibility that both genes contribute to both pathways, but *CFH* weakly to SDD and *ARMS2*
283 weakly to soft drusen.

284 CVD and stroke are the leading causes of death in the developed world. AMD is the
285 leading cause of blindness.⁴ Previous studies of AMD as a whole have failed to find consistent
286 relations between these diseases²⁴⁻²⁶ and in a large metanalysis, no associations.²⁷ However, SDD
287 and choroidal thinning specifically have been found to be associated with CAD in small
288 studies.^{2,3} SDD also confer decreased longevity,⁵ with vascular death suspected.^{2,3}
289 Histopathology of 1777 donor eyes¹⁷ found SDD, alone among AMD lesions, were associated
290 with cardiovascular death. We have shown herein additional convincing evidence that CVD and
291 stroke are strongly associated with the SDD/RMD type, not soft drusen.

292 The lipid dynamics of drusen with esterified cholesterol and SDD with non-esterified
293 cholesterol¹ are complex. Lipid in drusen and in the plaques of atherosclerotic disease (ASD) led
294 to a long search for common mechanisms in these lesions. However, it is increasingly clear that
295 drusen accumulation is associated with local blockage by abnormal BrM of normal absorption by
296 the choroidal circulation of lipids secreted by the RPE.¹ Further, as just reviewed, systemic
297 vascular disease is associated with RMD, not drusen.

298 The risk marker of low serum HDL for ASD actually runs contrary for AMD, with higher
299 HDL increasing risk.²⁸ This apparent paradox may now be explained: prior studies considered
300 only the drusen phenotype of AMD in color photos, and indeed, showed that high HDL is a risk

301 for drusen in AMD.²⁸ Low HDL is a risk for CVD and stroke, which we now have found is a risk
302 for RMD, the other AMD pathway. HDL cuts both ways, depending on the pathway.

303 The many (29/62) cases of pure RMD (without drusen) further suggest that RMD is a
304 distinct retinal pathology. Damage from RMD then can lead, along with that of soft drusen, to
305 advanced AMD, with similar presentations. It should be noted, however, that the lesions of
306 geographic atrophy consequent to drusen or RMD still have distinguishing morphologic⁷ and
307 autofluorescence characteristics,²⁹ consistent with different diseases.

308 The study has several weaknesses. The sample size is relatively small, so the results,
309 from a mostly Caucasian elderly population, require further examination in larger and diverse
310 cohorts e.g., in Asians, with the prevalent polypoidal choroidal vasculopathy form of AMD.³⁰
311 RMD status was determined by the presence of SDD alone, relying for CC insufficiency on the
312 quite consistent literature^{9 12,20} without direct verification by OCTA; this can be added in future
313 studies. Important drusen phenotypes other than soft drusen, such as calcified drusen and
314 cuticular drusen, have their own identified risk factors, but were not included. Larger studies
315 with greater power will be doubtless be needed to determine the associations of such phenotypes
316 with lesser prevalence. Vascular histories were patient reported and were verified from medical
317 records only in positive cases with stated heart disease or stroke. More detailed data on cardiac
318 and carotid status should be included in future studies to help interpret these results.

319 Strengths of this prospective study at two tertiary retina referral centers include rigorous
320 patient selection and AMD phenotyping with high quality multimodal imaging for drusen and
321 RMD. It is significant that the associations from 3 new fields, systemic vascular disease, serum
322 risks and genetic risks, further differentiate the drusen and RMD pathways with new data that
323 extend the already broad platform of existing evidence.

324

325 **Conclusion**

326 The SDD/RMD and soft drusen pathways, now considered to be components of one
327 disease, AMD, actually appear to be two separate, often co-existing diseases that only become
328 part of a single disease in their common outcome, advanced AMD.

329 There may be very real practical benefit from recognizing this pathophysiology. As
330 shown here, many AMD patients demonstrate only one of these index lesions. Patient care could
331 be personalized by consideration of the risk factors pertinent to such individuals. Research on the
332 pathogenesis of AMD could also be well-served by identifying and differentiating those risk
333 factors that apply specifically to only one or the other pathway. These distinctions could enable
334 focused attention on specific risks and single pathways, with correspondingly higher chances of
335 success. The specific association between systemic vascular disease and RMD in particular
336 merits further study in the context of the choroidal vascular insufficiency that accompanies SDD
337 and defines RMD.

338

339 Acknowledgment: we gratefully acknowledge several helpful conversations with Christine
340 Curcio.

341

342 **REFERENCES**

- 343 1. Oak AS, Messinger JD, Curcio CA. Subretinal drusenoid deposits: further
344 characterization by lipid histochemistry. *Retina*. 2014;34(4):825-826.
- 345 2. Cymerman RM, Skolnick AH, Cole WJ, Nabati C, Curcio CA, Smith RT. Coronary
346 Artery Disease and Reticular Macular Disease, a Subphenotype of Early Age-Related
347 Macular Degeneration. *Curr Eye Res*. 2016;41(11):1482-1488.
- 348 3. Ahmad M, Kaszubski PA, Cobbs L, Reynolds H, Smith RT. Choroidal thickness in
349 patients with coronary artery disease. *PLoS One*. 2017;12(6):e0175691.

- 350 4. Miller JW. Age-related macular degeneration revisited--piecing the puzzle: the LXIX
351 Edward Jackson memorial lecture. *Am J Ophthalmol.* 2013;155(1):1-35 e13.
- 352 5. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE. The epidemiology of retinal
353 reticular drusen. *Am J Ophthalmol.* 2008;145(2):317-326.
- 354 6. Pumariega NM, Smith RT, Sohrab MA, LeTien V, Souied EH. A prospective study of
355 reticular macular disease. *Ophthalmology.* 2011;118(8):1619-1625.
- 356 7. Xu L, Blonska AM, Pumariega NM, et al. Reticular macular disease is associated with
357 multilobular geographic atrophy in age-related macular degeneration. *Retina.*
358 2013;33(9):1850-1862.
- 359 8. Hayreh SS. In vivo choroidal circulation and its watershed zones. *Eye (Lond).* 1990;4(Pt
360 2):273-289.
- 361 9. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular disease. *Am J*
362 *Ophthalmol.* 2009;148(5):733-743.
- 363 10. Nesper PL, Soetikno BT, Fawzi AA. Choriocapillaris Nonperfusion is Associated With
364 Poor Visual Acuity in Eyes With Reticular Pseudodrusen. *Am J Ophthalmol.*
365 2017;174:42-55.
- 366 11. Cheng H, Kaszubski PA, Hao H, et al. The Relationship Between Reticular Macular
367 Disease and Choroidal Thickness. *Current eye research.* 2016;41(11):1492-1497.
- 368 12. Alten F, Clemens CR, Heiduschka P, Eter N. Localized reticular pseudodrusen and their
369 topographic relation to choroidal watershed zones and changes in choroidal volumes.
370 *Invest Ophthalmol Vis Sci.* 2013;54(5):3250-3257.
- 371 13. Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, Curcio CA. Sub-retinal
372 drusenoid deposits in human retina: organization and composition. *Exp Eye Res.*
373 2008;87(5):402-408.
- 374 14. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are
375 subretinal drusenoid deposits. *Ophthalmology.* 2010;117(2):303-312.e301.
- 376 15. Curcio CA, Messinger JD, Sloan KR, McGwin G, Jr, Medeiros NE, Spaide RF.
377 Subretinal drusenoid deposits in non-neovascular age-related macular degeneration:
378 morphology, prevalence, topography, and biogenesis model. *Retina.* 2013;33(2):265-276.
- 379 16. Wang J, Jiang J, Zhang Y, Qian YW, Zhang JF, Wang ZL. Retinal and choroidal vascular
380 changes in coronary heart disease: an optical coherence tomography angiography study.
381 *Biomed Opt Express.* 2019;10(4):1532-1544.
- 382 17. Mano F, Sprehe N, Olsen TW. Association of Drusen Phenotype in Age-Related Macular
383 Degeneration from Human Eye-Bank Eyes to Disease Stage and Cause of Death.
384 *Ophthalmol Retina.* 2020.
- 385 18. Sawa M, Ueno C, Gomi F, Nishida K. Incidence and characteristics of neovascularization
386 in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation.
387 *Retina.* 2014;34(4):761-767.
- 388 19. Flamendorf J, Agron E, Wong WT, et al. Impairments in Dark Adaptation Are
389 Associated with Age-Related Macular Degeneration Severity and Reticular
390 Pseudodrusen. *Ophthalmology.* 2015;122(10):2053-2062.
- 391 20. Alten F, Heiduschka P, Clemens CR, Eter N. Exploring choriocapillaris under reticular
392 pseudodrusen using OCT-Angiography. *Graefes Arch Clin Exp Ophthalmol.*
393 2016;254(11):2165-2173.

- 394 21. Yao H, Hou C, Liu W, Yi J, Su W, Hou Q. Associations of multiple serum biomarkers
395 and the risk of cardiovascular disease in China. *BMC Cardiovasc Disord.*
396 2020;20(1):426.
- 397 22. Lambert NG, ElShelmani H, Singh MK, et al. Risk factors and biomarkers of age-related
398 macular degeneration. *Progress in retinal and eye research.* 2016;54:64-102.
- 399 23. Smith RT, Merriam JE, Sohrab MA, et al. Complement factor H 402H variant and
400 reticular macular disease. *Archives of ophthalmology.* 2011;129(8):1061-1066.
- 401 24. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial
402 thromboembolic events in medicare neovascular age-related macular degeneration
403 patients. *Ophthalmology.* 2007;114(12):2174-2178.
- 404 25. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with
405 incident myocardial infarction among elderly Americans. *Ophthalmology.*
406 2007;114(4):732-737.
- 407 26. Keilhauer CN, Fritsche LG, Guthoff R, Haubitz I, Weber BH. Age-related macular
408 degeneration and coronary heart disease: evaluation of genetic and environmental
409 associations. *Eur J Med Genet.* 2013;56(2):72-79.
- 410 27. Wang J, Xue Y, Thapa S, Wang L, Tang J, Ji K. Relation between Age-Related Macular
411 Degeneration and Cardiovascular Events and Mortality: A Systematic Review and Meta-
412 Analysis. *Biomed Res Int.* 2016;2016:8212063.
- 413 28. Colijn JM, den Hollander AI, Demirkan A, et al. Increased High-Density Lipoprotein
414 Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-
415 RISK and European Eye Epidemiology Consortia. *Ophthalmology.* 2019;126(3):393-406.
- 416 29. Monés J, Biarnés M. Geographic atrophy phenotype identification by cluster analysis.
417 *British Journal of Ophthalmology.* 2017;102(3):388-392.
- 418 30. Wong CW, Wong TY, Cheung CM. Polypoidal Choroidal Vasculopathy in Asians. *J Clin*
419 *Med.* 2015;4(5):782-821.
- 420

421 **Figures and Legends:**

422

423 **Figure 1. Multimodal Imaging of Soft Drusen and Reticular Macular Disease (RMD) in**

424 **Age-related Macular Degeneration (AMD).**

425 **Left.** Near infrared reflectance (NIR) images. **Right.** Spectral domain optical coherence

426 tomography (SD-OCT) images. The green lines on the NIR images denote the location of the

427 corresponding B-scans on SD-OCT.

428

429 **A. Soft drusen. NIR** lesions of soft drusen have a hyperreflectant appearance. **SD-OCT.**

430 Soft drusen (blue arrowheads) lie between the basal lamina of the retinal pigment
431 epithelium (RPE) and the inner collagenous layer of Bruch's membrane (BrM), which is
432 seen intermittently where the RPE is elevated. The choroidal thickness in this case is 287
433 microns.

434 **B. Mixed drusen and RMD. NIR** lesions of RMD are fairly homogeneous and moderately
435 hypo-reflectant in a compact distribution with well-defined borders that is
436 pathognomonic for RMD. **SD-OCT.** SDD Stage II lesions between the RPE and ellipsoid
437 zone (EZ) are large enough to distort the EZ (yellow arrowheads). The choroidal
438 thickness in this case is 284 microns.

439 **C. Pure RMD. NIR** shows pathognomonic hypo-reflectant lesions, more numerous
440 superiorly as is usually the case. **SD-OCT.** A few stage I lesions not distorting the
441 overlying EZ are seen between the stage II SDD. In this pure RMD (no soft drusen) the
442 choroidal thickness is 213 microns, thinner than that in A and B, the soft drusen and
443 mixed phenotypes.

